• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Announces Extension of Share Repurchase Program to the Toronto Stock Exchange

    6/16/26 4:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email

    TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company,  announced today that it has filed with the Toronto Stock Exchange (the "TSX"), and the TSX has accepted, the Company's notice of intention to make a normal course issuer bid (the "TSX NCIB").

    As previously announced by Cronos, the Company's Board approved a share repurchase program on May 8, 2026, which commenced on May 14, 2026 and is expected to terminate on May 13, 2027, unless earlier terminated (the "Share Repurchase Program"). Pursuant to the TSX NCIB, repurchases under the Share Repurchase Program may now also be made from time to time pursuant to the facilities of the TSX and other alternative Canadian trading systems, in addition to being made through open market purchases at then-prevailing market prices through the facilities of the Nasdaq Global Market or other U.S. published markets, privately negotiated transactions or otherwise, as previously announced. Pursuant to the Share Purchase Agreement entered into on May 14, 2026, Celadon Financial Group, LLC has been appointed as the Company's agent to repurchase shares on its behalf. Any such repurchases will be executed through Virtu Canada Corp. when made over the facilities of the TSX or other alternative Canadian trading systems

    Pursuant to the Share Repurchase Program (including the TSX NCIB), Cronos intends to purchase for cancellation up to US$50 million of common shares in the capital of the Company (the "Common Shares") (in any case subject to a maximum of 18,712,918 Common Shares, representing approximately 5.02% of Cronos' 373 million issued and outstanding Common Shares as at June 1, 2026).

    Under the TSX NCIB, Cronos may purchase up to 53,968 of its Common Shares on the TSX during any trading day, which represents 25% of the average daily trading volume of 215,873 Common Shares on the TSX for the 6 months ended May 31, 2026, other than block purchase exemptions. Purchases under the TSX NCIB may commence on June 19, 2026 and continue until the date on which the Share Repurchase Program terminates as noted above.

    The TSX NCIB will be conducted in accordance with TSX rules and policies through the facilities of the TSX. The price that Cronos will pay for any Common Shares will be the market price prevailing at the time of purchase or such other price as may be permitted.

    Additionally, on June 15, 2026, Cronos obtained an exemption order (the "NCIB Exemption") from the Ontario Securities Commission, permitting Cronos to make repurchases under the Share Repurchase Program through the facilities of the NASDAQ and other United States-based trading systems in excess of the maximum that would otherwise be allowable under applicable Canadian securities laws absent an exemption. The NCIB Exemption allows Cronos to repurchase on such U.S. marketplaces up to the greater of 5 percent of Cronos's outstanding shares and 10 percent of Cronos' public float, provided that Cronos' aggregate repurchases on all marketplaces do not exceed this amount over the approximately 11-month period of the TSX NCIB, which is consistent with the maximum number of shares Cronos is able to purchase under the TSX NCIB. The other conditions to the NCIB Exemption will be outlined in Cronos' quarterly report on Form 10-Q for the quarter ended June 30, 2026 filed on EDGAR and SEDAR+.

    About Cronos

    Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

    Forward-Looking Information

    This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. The forward-looking information in this news release includes, but is not limited to, statements related to the Company's intention to commence the TSX NCIB and the timing and quantity of any purchases of Common Shares under the TSX NCIB and the Share Repurchase Program. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each of which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

    For further information, please contact:

    Harrison Aaron

    Investor Relations

    Tel: (416) 504-0004

    investor.relations@thecronosgroup.com



    Primary Logo

    Get the next $CRON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    More analyst ratings

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:49 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:02 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Buggy Shannon converted options into 20,622 shares and covered exercise/tax liability with 9,179 shares, increasing direct ownership by 7% to 178,322 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:57:28 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    SEC Filings

    View All

    Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Cronos Group Inc. (0001656472) (Filer)

    6/22/26 5:04:19 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Cronos Group Inc.

    10-Q - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:33:01 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:32:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders

    TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the "Meeting"), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for th

    6/22/26 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Announces Extension of Share Repurchase Program to the Toronto Stock Exchange

    TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company,  announced today that it has filed with the Toronto Stock Exchange (the "TSX"), and the TSX has accepted, the Company's notice of intention to make a normal course issuer bid (the "TSX NCIB"). As previously announced by Cronos, the Company's Board approved a share repurchase program on May 8, 2026, which commenced on May 14, 2026 and is expected to terminate on May 13, 2027, unless earlier terminated (the "Share Repurchase Program"). Pursuant to the TSX NCIB, repurchases under the Share Repurchase Program may now also be made from time t

    6/16/26 4:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Spinach® is the Number One Vape Brand in Canada

    TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabinoid company, today announced that its Spinach® vape portfolio has become the top‑selling vape brand in Canada, capturing 10.4%1 market share of the total vapes category in April 2026, a position that Cronos has held since January 2026. Since entering the vape category, the Spinach® brand has built a best‑in‑class offering rooted in quality, flavor, and technology. Spinach® vapes are crafted using high‑purity extracts, feature vibrant and distinctive terpene profiles, and utilize advanced hardware designed to deliver smooth, reliable performance for adult consumers

    6/11/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Cronos Group

    Canaccord Genuity initiated coverage of Cronos Group with a rating of Buy

    1/27/26 9:29:20 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026

    TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    4/20/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    2/12/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025

    TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

    10/23/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders

    TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the "Meeting"), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for th

    6/22/26 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    3/19/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    12/19/22 8:47:03 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care